--- title: "Precigen (PGEN) news: offering and convertible notes" url: "https://aibio.space/companies/precigen/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PGEN offering and convertible notes news: Precigen agrees to $79.0 million private placement of convertible preferred stock. Precigen, Inc." --- PGEN Precigen, Inc. NASDAQ · United States # Precigen (PGEN) news PGEN offering and convertible notes news Debt Financing · 2025-09-03 ## [Precigen draws $100.0 million at closing of Pharmakon senior secured term loan facility](https://aibio.space/news/precigen-draws-100-0-million-closing-pharmakon-senior-secured-term/) Precigen entered a five-year senior secured loan agreement with funds managed by Pharmakon Advisors. A $25.0 million delayed draw tranche is available until June 29, 2027, and the loans mature September 3, 2030. ## Latest Precigen news 1. 2024-12-30 Financings [Precigen agrees to $79.0 million private placement of convertible preferred stock](https://aibio.space/news/precigen-agrees-79-0-million-private-placement-convertible-preferred/) Precigen agreed to sell 8.00% Series A convertible perpetual preferred stock for anticipated gross proceeds of $79.0 million, with warrants for 52,666,669 shares at $0.75 attached. The company says the money extends its cash runway into 2026, provided the PRGN-2012 launch comes after approval. ## Precigen at a glance - **Ticker**: PGEN - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $38.2 million ### Related companies - [Elutia](https://aibio.space/companies/elutia/) NASDAQ: ELUT - [Longeveron](https://aibio.space/companies/longeveron/) NASDAQ: LGVN - [Cel-Sci](https://aibio.space/companies/cel-sci/) AMEX: CVM - [Rapport Therapeutics](https://aibio.space/companies/rapport-therapeutics/) NASDAQ: RAPP - [MindWalk Holdings](https://aibio.space/companies/mindwalk/) NASDAQ: HYFT - [Aridis Pharmaceuticals](https://aibio.space/companies/aridis-pharmaceuticals/) OTC: ARDS - [Alector](https://aibio.space/companies/alector/) NASDAQ: ALEC - [Trevi Therapeutics](https://aibio.space/companies/trevi-therapeutics/) NASDAQ: TRVI ### Also on NASDAQ - [PRF Technologies](https://aibio.space/companies/prf-technologies/) PRFX - [Aclaris Therapeutics](https://aibio.space/companies/aclaris-therapeutics/) ACRS - [Latigo Biotherapeutics](https://aibio.space/companies/latigo-biotherapeutics/) LTGO - [Veraxa Biotech](https://aibio.space/companies/veraxa-biotech/) VRXA - [Nutriband](https://aibio.space/companies/nutriband/) NTRB - [Canopy Growth](https://aibio.space/companies/canopy-growth/) CGC ## What Precigen does Precigen, Inc. is a commercial-stage biopharmaceutical company developing precision medicines in immuno-oncology, autoimmune disorders and infectious diseases. Its platforms include AdenoVerse immunotherapy, UltraCAR-T and the UltraPorator electroporation device. In August 2025 the FDA granted full approval to Papzimeos (zopapogene imadenovec-drba, PRGN-2012) for adults with recurrent respiratory papillomatosis, a rare disease caused by chronic HPV 6 or HPV 11 infection. The clinical pipeline includes PRGN-2009, based on AdenoVerse, in Phase 2 trials under a cooperative research and development agreement with the National Cancer Institute in recurrent or metastatic cervical cancer and newly diagnosed HPV-associated oropharyngeal cancer. Enrollment in the Phase 1b trial of PRGN-3006, an UltraCAR-T candidate, has been completed. In August 2024 the company paused enrollment in the PRGN-3005 and PRGN-3007 trials as part of portfolio prioritization. The company also uses Sleeping Beauty, a non-viral transposon system licensed from the University of Texas MD Anderson Cancer Center, to deliver gene programs. | Product or program | What it is | Stage | |---|---|---| | Papzimeos (zopapogene imadenovec-drba, PRGN-2012) | Non-replicating adenoviral vector immunotherapy for recurrent respiratory papillomatosis | Approved in the US (full approval, August 2025) | | PRGN-2009 | AdenoVerse immunotherapy for cervical and HPV-associated oropharyngeal cancers | Phase 2 under CRADA with the National Cancer Institute | | PRGN-3006 | UltraCAR-T therapy candidate | Phase 1b, enrollment completed | | PRGN-3005 | UltraCAR-T therapy candidate | Clinical trial enrollment paused in August 2024 | | PRGN-3007 | UltraCAR-T therapy candidate | Clinical trial enrollment paused in August 2024 | Summarised from the company's [10-K filed Mar 25, 2026](https://www.sec.gov/Archives/edgar/data/1356090/000135609026000009/pgen-20251231.htm). ## Precigen annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$41.3 million](https://www.sec.gov/Archives/edgar/data/1356090/000135609026000009/) | [$53.1 million](https://www.sec.gov/Archives/edgar/data/1356090/000135609026000009/) | | Net income (loss) | [-$250.6 million](https://www.sec.gov/Archives/edgar/data/1356090/000135609026000009/) | [-$126.2 million](https://www.sec.gov/Archives/edgar/data/1356090/000135609026000009/) | | Cash from operations | [-$87.8 million](https://www.sec.gov/Archives/edgar/data/1356090/000135609026000009/) | [-$68.2 million](https://www.sec.gov/Archives/edgar/data/1356090/000135609026000009/) | | Cash and equivalents | [$30.2 million](https://www.sec.gov/Archives/edgar/data/1356090/000135609026000030/) | [$29.5 million](https://www.sec.gov/Archives/edgar/data/1356090/000135609026000009/) | | Short-term investments | [$67.6 million](https://www.sec.gov/Archives/edgar/data/1356090/000135609026000030/) | [$68.4 million](https://www.sec.gov/Archives/edgar/data/1356090/000135609026000009/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $16.3 million, plus short-term investments of $21.9 million, $38.2 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Precigen Has Precigen raised money recently? Our latest story on this, dated Dec 30, 2024: "Precigen agrees to $79.0 million private placement of convertible preferred stock". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/precigen-agrees-79-0-million-private-placement-convertible-preferred/). Has Precigen sold convertible notes? Our latest story on this, dated Dec 30, 2024: "Precigen agrees to $79.0 million private placement of convertible preferred stock". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/precigen-agrees-79-0-million-private-placement-convertible-preferred/). What is the ticker symbol of Precigen? Precigen, Inc. trades under the ticker PGEN on NASDAQ. Where is Precigen listed? Precigen, Inc. is listed on NASDAQ. Our directory also records these other listings: BX:I5X; GETTEX:I5X; LS:A2PZG1; LSX:A2PZG1. What is the SEC CIK of Precigen? The SEC Central Index Key (CIK) for Precigen, Inc. is 1356090. Its filings are on SEC EDGAR. How many shares does Precigen have outstanding? 358,035,247 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-04. Which country or territory is Precigen listed under? Our directory records Precigen, Inc. under United States. What does Precigen do? Our directory classifies Precigen, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Precigen? The ISIN recorded for Precigen, Inc. is US74017N1054. Does aibio.space cover Precigen? aibio.space lists Precigen, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Precigen incorporated? SEC records list its state or country of incorporation as VA. What does Precigen develop? Precigen, Inc. is a commercial-stage biopharmaceutical company developing precision medicines in immuno-oncology, autoimmune disorders and infectious diseases. Its platforms include AdenoVerse immunotherapy, UltraCAR-T and the UltraPorator electroporation device. What is Papzimeos (zopapogene imadenovec-drba, PRGN-2012) from Precigen? Papzimeos (zopapogene imadenovec-drba, PRGN-2012): Non-replicating adenoviral vector immunotherapy for recurrent respiratory papillomatosis Stage: Approved in the US (full approval, August 2025). What is PRGN-2009 from Precigen? PRGN-2009: AdenoVerse immunotherapy for cervical and HPV-associated oropharyngeal cancers Stage: Phase 2 under CRADA with the National Cancer Institute. Is Precigen profitable? Precigen, Inc. reported a net loss of $250.6 million for the fiscal year ended Dec 31, 2025, and used $87.8 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Precigen Members talk about Precigen (PGEN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Precigen, newest first. Each line links the filing it comes from. 1. 2025-09-17 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). [Source](https://www.sec.gov/Archives/edgar/data/1356090/000095010325011775/dp234458_8k.htm) 2. 2025-08-19 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1356090/000095010325010472/dp233112_s3.htm) 3. 2025-06-30 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1356090/000095010325008124/dp230886_8k.htm) 4. 2025-01-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1356090/000095010325000576/dp223534_8k.htm) 5. 2024-12-30 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1356090/000095010324018479/dp222802_ex9901.htm) 6. 2024-11-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1356090/000095010324016076/dp220472_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PGEN on TradingView](https://www.tradingview.com/symbols/NASDAQ-PGEN/). ## SEC filings and registration - **SEC name**: Precigen, Inc. - **CIK**: 1356090 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PGEN (Nasdaq) - **State or country of incorporation**: VA - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, 20876 - **Phone**: 301-556-9900 - **Shares outstanding**: 358,035,247 as of 2026-07-31 (10-Q filed 2026-08-04) - **Former names**: INTREXON CORP ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1356090/000135609026000030/pgen-20260630.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1356090/000095010326011876/dp251262_8k.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1356090/000095010326009441/dp248898_8k.htm) filed 2026-06-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1356090/000095010326007158/dp246650_8k.htm) filed 2026-05-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1356090/000135609026000017/pgen-20260331.htm) filed 2026-05-13 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1356090/000114036126018214/ny20068828x1_def14a.htm) filed 2026-04-30 - [10-K](https://www.sec.gov/Archives/edgar/data/1356090/000135609026000009/pgen-20251231.htm) filed 2026-03-25 - [8-K](https://www.sec.gov/Archives/edgar/data/1356090/000095010326004648/dp244075_8k.htm) filed 2026-03-25 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001356090), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Precigen, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PGEN, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Precigen, Inc. - **Ticker**: PGEN - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US74017N1054 - **Other listed symbols**: BX:I5X; GETTEX:I5X; LS:A2PZG1; LSX:A2PZG1 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PGEN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/precigen/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Precigen (PGEN) news: offering and convertible notes", 2026-10-31, https://aibio.space/companies/precigen/